Loading clinical trials...
Loading clinical trials...
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT06608446 · Breast Neoplasms
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more
NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, and more
NCT07174336 · Breast Neoplasms, Neoplasm Metastasis
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nashville, Tennessee
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Katy, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions